Current tumor classification based on appearance of the cells may not identify subgroups that are distinctly different on molecular analysis and may have significantly different clinical outcome. Such molecular heterogeneity has been discovered in diffuse large B-cell lymphoma that explains why some of the patients with seemingly the same disease respond to therapy and have prolonged survival while the rest succumb to the disease.
Go to Previous Page
Go to Next Page